Angiotensin II, oxidative stress and skeletal muscle wasting

American Journal of the Medical Sciences

Volumn 342, Issue 2, 2011, Pages 143-147

  Sukhanov, Sergiy ^a   Semprun Prieto, Laura ^a   Yoshida, Tadashi ^a   Tabony, A Michael ^a   Higashi, Yusuke ^a   Galvez, Sarah ^a   Delafontaine, Patrice ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Muscle atrophy; Oxidative stress

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ATROGIN 1; CATECHOLAMINE; ENDOTHELIN 1; MUSCLE RING FINGER 1 PROTEIN; PROTEASOME; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UBIQUITIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALDOSTERONE RELEASE; CACHEXIA; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; KIDNEY FAILURE; MOLECULAR INTERACTION; MUSCLE ATROPHY; MUSCLE MITOCHONDRION; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UPREGULATION;

EID: 79961032293     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318222e620     Document Type: Conference Paper

References (59)

1. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349: 1050-3. (Pubitemid 27158249)
2. Marcell TJ. Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci 2003;58:M911-6.
3. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 2003;5:87-90. (Pubitemid 36204186)
4. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-8. (Pubitemid 33104839)
5. Gomes MD, Lecker SH, Jagoe RT, et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001;98:14440-5. (Pubitemid 33121410)
6. Stevenson EJ, Giresi PG, Koncarevic A, et al. Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle. J Physiol 2003;551(Pt 1):33-48. (Pubitemid 37062910)
7. Price SR. Increased transcription of ubiquitin-proteasome system components: molecular responses associated with muscle atrophy. Int J Biochem Cell Biol 2003;35:617-28. (Pubitemid 36369510)
8. Wang XH, Zhang L, Mitch WE, et al. Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. J Biol Chem 2010;285:21249-57.
9. Lecker SH, Jagoe RT, Gilbert A, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004;18:39-51. (Pubitemid 38076464)
10. Khal J, Hine AV, Fearon KC, et al. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol 2005;37:2196-206. (Pubitemid 41206831)
11. Mitch WE, Bailey JL, Wang X, et al. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol 1999;276(5 Pt 1):C1132-8. (Pubitemid 29244668)
12. Murgia M, Serrano AL, Calabria E, et al. Ras is involved in nerve-activity-dependent regulation of muscle genes. Nat Cell Biol 2000;2:142-7.
13. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001;3:1014-9. (Pubitemid 34428747)
14. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001;3:1009-13. (Pubitemid 34428746)
15. Pallafacchina G, Calabria E, Serrano AL, et al. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc Natl Acad Sci USA 2002;99: 9213-8. (Pubitemid 34764593)
16. Sacheck JM, Ohtsuka A, McLary SC, et al. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophyrelated ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 2004;287:E591-601. (Pubitemid 39242684)
17. Sandri M, Sandri C, Gilbert A, et al. FoxO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004;117:399-412. (Pubitemid 38534545)
18. Werner C, Poss J, Bohm M. Optimal antagonism of the Renin-Angiotensin- aldosterone system: do we need dual or triple therapy? Drugs 2010;70:1215-30.
19. Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008;11:400-7.
20. Masson S, Latini R, Bevilacqua M, et al. Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res 1998;37:213-7. (Pubitemid 28174854)
21. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21:53-7. (Pubitemid 30042669)
22. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-83. (Pubitemid 36369559)
23. Sanders PM, Russell ST, Tisdale MJ. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer 2005;93: 425-34. (Pubitemid 43080016)
24. de Kloet AD, Krause EG, Kim DH, et al. The effect of angiotensinconverting enzyme inhibition using captopril on energy balance and glucose homeostasis. Endocrinology 2009;150:4114-23.
25. de Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic syndrome. Physiol Behav 2010;100:525-34.
26. de Kloet AD, Woods SC. Molecular neuroendocrine targets for obesity therapy. Curr Opin Endocrinol Diabetes Obes 2010;17:441-5.
27. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 1996;97:2509-16. (Pubitemid 26187338)
28. Brink M, Price SR, Chrast J, et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 2001;142:1489-96. (Pubitemid 32299677)
29. Song YH, Li Y, Du J, et al. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005;115:451-8. (Pubitemid 40385487)
30. Yoshida T, Semprun-Prieto L, Sukhanov S, et al. IGF-1 prevents ANG II-induced skeletal muscle atrophy via AKT-and FoxO-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am J Physiol Heart Circ Physiol 2010;298:H1565-70.
31. Diamond-Stanic MK, Henriksen EJ. Direct inhibition by angiotensin II of insulin-dependent glucose transport activity in mammalian skeletal muscle involves a ROS-dependent mechanism. Arch Physiol Biochem 2010;116:88-95.
32. Stegbauer J, Coffman TM. New insights into angiotensin receptor actions: from blood pressure to aging. Curr Opin Nephrol Hypertens 2011;20:84-8.
33. Russell ST, Sanders PM, Tisdale MJ. Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett 2006;231:290-4. (Pubitemid 43038740)
34. Zhang L, Du J, Hu Z, et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 2009;20:604-12.
35. May RC, Kelly RA, Mitch WE. Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism. J Clin Invest 1986;77:614-21. (Pubitemid 16037664)
36. Wing SS, Goldberg AL. Glucocorticoids activate the ATP-ubiquitindependent proteolytic system in skeletal muscle during fasting. Am J Physiol 1993;264(4 Pt 1):E668-76. (Pubitemid 23118183)
37. May RC, Bailey JL, Mitch WE, et al. Glucocorticoids and acidosis stimulate protein and amino acid catabolism in vivo. Kidney Int 1996;49:679-83. (Pubitemid 26093076)
38. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13(8 Suppl B):9-20.
39. Jenkins TA, Allen AM, Chai SY, et al. Interactions of angiotensin II with central catecholamines. Clin Exp Hypertens 1995;17:267-80.
40. Rossi GP, Sacchetto A, Cesari M, et al. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999;43:300-7. (Pubitemid 29356368)
41. Apel K, Hirt H. Reactive oxygen species: metabolism, oxidative stress, and signal transduction. Annu Rev Plant Biol 2004;55:373-99. (Pubitemid 38940937)
42. Kaneto H, Katakami N, Matsuhisa M, et al. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm 2010;2010:453892.
43. Kondo H. Handbook of oxidants and antioxidants in exercise. 1st ed. Amsterdam; New York: Elsevier; 2000. p. 631-53.
44. Appell HJ, Duarte JA, Soares JM. Supplementation of vitamin E may attenuate skeletal muscle immobilization atrophy. Int J Sports Med 1997;18:157-60.
45. Ikemoto M, Nikawa T, Kano M, et al. Cysteine supplementation prevents unweighting-induced ubiquitination in association with redox regulation in rat skeletal muscle. Biol Chem 2002;383:715-21. (Pubitemid 34506309)
46. Powers SK, Kavazis AN, DeRuisseau KC. Mechanisms of disuse muscle atrophy: role of oxidative stress. Am J Physiol Regul Integr Comp Physiol 2005;288:R337-44. (Pubitemid 40129594)
47. McClung JM, Judge AR, Powers SK, et al. p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol 2010;298:C542-9.
48. Whitehead NP, Yeung EW, Froehner SC, et al. Skeletal muscle NADPH oxidase is increased and triggers stretch-induced damage in the mdx mouse. PLoS One 2010;5:e15354.
49. Muller FL, Song W, Jang YC, et al. Denervation-induced skeletal muscle atrophy is associated with increased mitochondrial ROS production. Am J Physiol Regul Integr Comp Physiol 2007;293:R1159-68. (Pubitemid 47358937)
50. Zhao W, Swanson SA, Ye J, et al. Reactive oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin II-dependent hypertension. Hypertension 2006;48:637-43. (Pubitemid 44848210)
51. Wei Y, Sowers JR, Nistala R, et al. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 2006;281:35137-46. (Pubitemid 46036553)
52. Dai DF, Johnson SC, Villarin JJ, et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and G{alpha}q overexpression-induced heart failure. Circ Res 2011;108:837-46.
53. Semprun-Prieto L, Sukhanov S, Yoshida T, et al. Angiotensin II induced muscle wasting is redox dependent: differential requirement of p47 phox in the anorexigenic and catabolic effects of angiotensin II [Abstract 3578]. Circulation 2009:120(18 MeetingAbstracts):S829.
54. Semprun-Prieto L, Sukhanov S, Yoshida T, et al. Skeletal musclespecific overexpression of insulin-like growth factor 1 decreases ocidative stress and prevents angiotensin II-induced skeletal muscle wasting: novel potential therapy to treat cachexia in congestive heart failure. In: AFMR Southern Regional Meeting; New Orleans, LA, February 12-14, 2009 [Abstract]. J Investig Med 2009;57:320.
55. Sukhanov S, Semprun-Prieto L, Yoshida T, et al. Dual oxidase involvement in angiotensin II-induced oxidative stress in wasted skeletal muscle. In: Southern Regional Meeting, February 25-27, 2010 [Abstract]. J Investig Med 2010;58:443.
56. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008;102:488-96. (Pubitemid 351651106)
57. Daiber A. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim Biophys Acta 2010;1797:897-906.
58. Wosniak J Jr, Santos CX, Kowaltowski AJ, et al. Cross-talk between mitochondria and NADPH oxidase: effects of mild mitochondrial dysfunction on angiotensin II-mediated increase in Nox isoform expression and activity in vascular smooth muscle cells. Antioxid Redox Signal 2009;11:1265-78.
59. Kimura S, Zhang GX, Nishiyama A, et al. Role of NAD(P)H oxidase-and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension 2005;45:860-6. (Pubitemid 40628929)